<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03396731</url>
  </required_header>
  <id_info>
    <org_study_id>FSK-VLU-004</org_study_id>
    <nct_id>NCT03396731</nct_id>
  </id_info>
  <brief_title>Efficacy Study for Geko Device in VLU Patients</brief_title>
  <official_title>A Prospective, Multicentre, Randomised, Assessor Blinded Study Comparing the Efficacy, Including Patient Reported Outcomes of Two Different Daily gekoTM Treatment Durations in Conjunction With Standard Care, With Each Other and to Standard Care Alone, in Patients With Venous Leg Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Firstkind Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Firstkind Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eight weeks, comprised of four weeks Run-in Phase of Standard Care (SC) treatment followed by&#xD;
      four weeks of treatment allocated by randomisation (Treatment Phase).&#xD;
&#xD;
      To compare two daily geko™ device treatment durations, six hours and 12 hours, in conjunction&#xD;
      with SC, with each other and to SC alone, in patients with venous leg ulcers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Screen patient database to identify eligible patients&#xD;
&#xD;
        2. Obtain informed consent and inform participant's GP&#xD;
&#xD;
        3. Complete CRF throughout the study period (demographics, vital signs, medical history,&#xD;
           study ulcer history, concomitant medication)&#xD;
&#xD;
        4. Physical examination at the study start up visit and at consecutive weekly visits&#xD;
&#xD;
        5. Take a digital image of the wound at participants weekly visits&#xD;
&#xD;
        6. Assess and report adverse events&#xD;
&#xD;
        7. Apply standard care (compression bandaging) at weekly visits and record all the dressing&#xD;
           usage&#xD;
&#xD;
        8. Perform randomisation at the end of week 4 and allocate participant to one of the three&#xD;
           treatment groups.&#xD;
&#xD;
        9. Train the participant to use gekoTM devices&#xD;
&#xD;
       10. Schedule weekly visits&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The assessors will be blinded to the study participants and what treatment they are receiving.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Linear healing rate (LHR)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Linear healing rate will be studied on a weekly basis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound healing rate</measure>
    <time_frame>Upto 8 weeks</time_frame>
    <description>Measured with the images taken</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain reduction</measure>
    <time_frame>Upto 8 weeks</time_frame>
    <description>Participant reported outcome of pain reduction using Visual Analogue Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>Upto 8 weeks</time_frame>
    <description>Change in Quality of Life based on participant reported outcomes using EQ-5D-5L questionnaire</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Venous Leg Ulcer</condition>
  <condition>Leg Ulcers Venous</condition>
  <condition>Leg Ulcer</condition>
  <condition>Wound Leg</condition>
  <condition>Wound</condition>
  <arm_group>
    <arm_group_label>Standard care alone (control)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Multilayer/multi component compression bandaging treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 hours geko™ (no longer recruiting)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>geko™ device 6 hours daily for 4 weeks treatment phase, to be used in conjunction with Standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 hours geko™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>geko™ device 12 hours daily for 4 weeks treatment phase, to be used in conjunction with Standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>geko™ medical device</intervention_name>
    <description>The geko™ device, manufactured by Firstkind Ltd (High Wycombe, United Kingdom), is a small disposable, battery powered CE marked medical device.</description>
    <arm_group_label>12 hours geko™</arm_group_label>
    <arm_group_label>6 hours geko™ (no longer recruiting)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Potential subjects are required to meet all of the following criteria for enrollment into&#xD;
        the study and subsequent randomization.&#xD;
&#xD;
          1. Male or female aged ≥ 18 years and able to provide written informed consent.&#xD;
&#xD;
          2. Intact healthy skin at the site of gekoTM device application.&#xD;
&#xD;
          3. Patients who have a chronic venous leg ulcer determined to be due to underlying venous&#xD;
             disease following evaluation in a multidisciplinary clinic setting.&#xD;
&#xD;
          4. A VLU of approximately ≥ 3cm2 and ≤ 39 cm2 at study enrolment i.e. Run In Phase Visit&#xD;
             1 (RV1). The largest ulcer within the given size range will be designated the study&#xD;
             ulcer and the only one included in the study. If other ulcerations are present on the&#xD;
             same leg they have to be more than 2 cm apart if they are separate wounds.&#xD;
&#xD;
          5. Study ulcer (current episode of ulceration in case of ulcer recurrence) has been&#xD;
             present for at least 6 weeks but no more than 5 years prior to study entry (i.e. RV1).&#xD;
&#xD;
          6. Ankle-Brachial Pressure Index (ABPI) of 0.75-1.24 inclusive measured at study entry or&#xD;
             within 8 weeks prior to study entry (i.e. RV1).&#xD;
&#xD;
          7. No active local or systemic infection for a minimum of 48 hours prior to study entry&#xD;
             (i.e. RV1).&#xD;
&#xD;
          8. No systemic antimicrobial treatment for a minimum of seven days prior to study entry&#xD;
             prescribed for index wound infection (i.e. RV1).&#xD;
&#xD;
          9. Patient understands and is willing to participate in the study and is able to comply&#xD;
             with study procedures and visits.&#xD;
&#xD;
        Note: At the randomisation visit, the study ulcer needs to be ≥ 2 cm2 and ≤ 30 cm2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Potential subjects meeting any of the following criteria will be excluded from enrollment&#xD;
        and subsequent randomisation:&#xD;
&#xD;
          1. Known allergy to any of the protocol-stipulated treatments, or non-tolerance of&#xD;
             multilayer, multicomponent compression therapy.&#xD;
&#xD;
          2. History of significant haematological disorders (e.g. Sickle Cell disease).&#xD;
&#xD;
          3. History of Deep Vein Thrombosis (DVT) within six months preceding study entry (i.e.&#xD;
             RV1).&#xD;
&#xD;
          4. History of Pyoderma Gangrenosum or other inflammatory ulceration.&#xD;
&#xD;
          5. Pregnancy or breast feeding.&#xD;
&#xD;
          6. Use of investigational drug or device within four weeks prior to study entry (i.e.&#xD;
             RV1) that may interfere with this study.&#xD;
&#xD;
          7. Use of any neuro-modulation device.&#xD;
&#xD;
          8. Surgery during three months prior to study entry (such as abdominal, gynaecological,&#xD;
             hip or knee replacement) (i.e. RV1).&#xD;
&#xD;
          9. Trauma to the lower limbs that would prevent geko™ from stimulating the common&#xD;
             peroneal nerve.&#xD;
&#xD;
         10. No involuntary movement of the lower leg/foot at the maximum tolerable device setting.&#xD;
&#xD;
         11. Any medication deemed by the Investigator to potentially interfere with the study&#xD;
             treatment (e.g. systemic steroids).&#xD;
&#xD;
         12. Participation in any other clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Harding, FRCGP FRCP FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Welsh Wound Innovation Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kieron Day</last_name>
    <phone>01494572042</phone>
    <email>Kieron.Day@firstkindmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Therese Targett, PhD</last_name>
    <phone>07340903377</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Trafalgar Group Medical Practice</name>
      <address>
        <city>Southsea</city>
        <state>Portsmouth</state>
        <zip>PO5 3ND</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shruti Singh</last_name>
      <email>shrutisingh@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Shruti Singh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Crouch Oak Family Practice</name>
      <address>
        <city>Addlestone</city>
        <zip>KT15 2BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Barnsley Hospital NHS foundation Trust</name>
      <address>
        <city>Barnsley</city>
        <zip>S75 2EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Lancaster</last_name>
      <email>nicola.lancaster2@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Kay Baxter, LL.B FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart of Bath Medical Partnership</name>
      <address>
        <city>Bath</city>
        <zip>BA2 3HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Cumpson</last_name>
      <email>becky.cumpson@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Tim Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Walk Surgery</name>
      <address>
        <city>Bristol</city>
        <zip>BS37 4AX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Rowden Surgery</name>
      <address>
        <city>Chippenham</city>
        <zip>SN15 2NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Lakeside Healthcare</name>
      <address>
        <city>Corby</city>
        <zip>NN17 2UR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter NHS Foundation Trust</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo Clarke</last_name>
      <email>joanne.clarke10@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Juliet Price</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Tyneside NHS Foundation Trust</name>
      <address>
        <city>Hebburn</city>
        <zip>NE31 1AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust</name>
      <address>
        <city>Kings Lynn</city>
        <zip>PE30 4ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Waterfield</last_name>
      <email>Kelly.Waterfield@qehkl.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Chandana Wijewardena, MS FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lancashire Care NHS Trust</name>
      <address>
        <city>Leyland</city>
        <zip>PR25 2TN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Morgan</last_name>
      <email>Kathryn.Morgan@lancashirecare.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Kathryn Morgan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Accelerate CIC</name>
      <address>
        <city>London</city>
        <zip>E1 4DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Staines</last_name>
      <email>Karen.staines@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Richard Bull</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Central London Community Healthcare</name>
      <address>
        <city>London</city>
        <zip>W10 6DZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnes Collarte</last_name>
      <email>agnes.collarte@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Agnes Collarte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norfolk Community Health and Care NHS Trust</name>
      <address>
        <city>Norwich</city>
        <zip>NR2 3TU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Clements</last_name>
      <email>donna.clements@nchc.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Joanne Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>The Adam Practice</name>
      <address>
        <city>Poole</city>
        <zip>BH16 5PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hertfordshire Community NHS Trust</name>
      <address>
        <city>Stevenage</city>
        <zip>SG1 2UA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Musgrove Park Hospital</name>
      <address>
        <city>Taunton</city>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Breckland Alliance</name>
      <address>
        <city>Thetford</city>
        <zip>IP24 2HY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Welsh wound Innovation Centre</name>
      <address>
        <city>Wales</city>
        <zip>CF72 8UX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicky Ivins</last_name>
      <email>Nicky.Ivins@wwic.wales</email>
    </contact>
    <investigator>
      <last_name>Nicky Ivins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Worcestershire Royal Hospital</name>
      <address>
        <city>Worcester</city>
        <zip>WR5 1HN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>York Teaching Hospital NHS Foundation Trust</name>
      <address>
        <city>York</city>
        <zip>YO31 8HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.gekodevices.com/en-uk/</url>
    <description>Device official website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 12, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2018</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VLU</keyword>
  <keyword>Venous Leg Ulcer</keyword>
  <keyword>Leg Ulcer</keyword>
  <keyword>Leg Wound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

